Flamingo Therapeutics Shares Insights on Immune Modulation at AACR
Flamingo Therapeutics is excited to reveal that an abstract concerning their notable research on danvatirsen has been accepted for presentation at a prestigious annual meeting of the American Association for Cancer Research (AACR). This event occurs while at the forefront of cancer research, bringing together thought leaders and innovators dedicated to advancing the fight against cancer. The presentation highlights the immune-modulatory effects of danvatirsen, an agent designed to enhance the effectiveness of immunotherapies.
Details of the Presentation
The poster presentation at the AACR will feature the following highlights:
Poster Title: "ASO-mediated STAT3 knockdown relieves immunosuppression sensitizing tumors to immunotherapies"
Session Category/Title: Immunology/Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression
Session Time: April 28, 2025, from 9:00 AM to 12:00 PM
Location: Poster Section 38
Published Abstract Number: 2244
About Flamingo Therapeutics
Flamingo Therapeutics is at the forefront of revolutionizing cancer treatment through innovative RNA-targeted therapies. They focus on effectively addressing complex challenges in oncology, particularly those involving difficult-to-target transcription factors and long non-coding RNAs. The company has formed a strategic partnership with Ionis Pharmaceuticals to enhance the development of their clinical pipeline.
Flamingo also enjoys support from notable biotechnology investors, which includes Abrdn, Andera Partners, and Bpifrance, among others. This funding is crucial as it enables Flamingo to pursue groundbreaking research and clinical studies that could significantly impact cancer care.
Current Clinical Trials Involving Danvatirsen
Flamingo has initiated a Phase II clinical trial known as 'PEMDA-HN'. This study evaluates the effects of danvatirsen, focused on targeting the STAT3 protein in combination with pembrolizumab for patients suffering from head and neck squamous cell carcinoma (HNSCC). The trial aims to determine how effectively this combination can enhance treatment outcomes for this challenging cancer.
Additionally, a Phase I investigator-initiated trial is underway that assesses danvatirsen as a monotherapy and in conjunction with venetoclax in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These trials underscore Flamingo's commitment to advancing available treatment options in oncology.
Engage With Flamingo Therapeutics
Flamingo Therapeutics encourages individuals interested in their work and developments in the field of cancer research to engage with them on social media platforms. They are active on LinkedIn, providing regular updates regarding their research initiatives, clinical trials, and corporate developments. As a company dedicated to transparency and collaboration, Flamingo welcomes community engagement.
Frequently Asked Questions
What is the focus of Flamingo Therapeutics?
Flamingo Therapeutics specializes in RNA-targeted therapies for innovative cancer treatments.
What is the significance of the AACR annual meeting?
The AACR annual meeting is a major event where researchers present their latest findings in cancer research, contributing to the scientific conversation around oncology.
How does danvatirsen work?
Danvatirsen targets the STAT3 protein, aiming to reduce immunosuppression within tumors and make them more receptive to immunotherapies.
What types of cancer are being targeted in Flamingo's trials?
Flamingo Therapeutics focuses on head and neck squamous cell carcinoma and acute myeloid leukemia, among other cancers.
How can I learn more about Flamingo Therapeutics?
To discover more about Flamingo Therapeutics, visit their official website or follow their updates on LinkedIn.
